查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1318904

中樞神經系統藥物市場：依分類、疾病、藥物類型、通路 - 全球預測 2023-2030

Central Nervous System Drugs Market by Drug Classes, Diseases, Drug Type, Distribution Channel - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球中樞神經系統藥物市場預計2023年將大幅成長至207.1億美元，年複合成長率為9.60%，預計到2030年將達到驚人的399.9億美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球中樞神經系統藥物市場至關重要。透過檢查業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發領域、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.全球中樞神經系統藥物市場規模及預測如何？

2.在預測期內，COVID-19對全球中樞神經系統藥物市場的阻礙因素與影響為何？

3.在預測期內，全球中樞神經系統藥物市場需要投資哪些產品/細分市場/應用/領域？

4.全球中樞神經系統藥物市場的競爭策略為何？

5. 全球中樞神經系統藥物市場的技術趨勢和法律規範是什麼？

6.全球中樞神經系統藥物市場主要供應商的市佔率為何？

7. 哪些型態和策略性措施被認為適合進入全球中樞神經系統藥物市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 促進因素
      • 全球神經病變和認知障礙的發生率不斷增加
      • 加強政府計畫和宣傳活動，傳播神經系統危險因子和症狀的知識
      • 患有神經系統併發症的老年人口不斷增加
    • 抑制因素
      • 藥物研發和開發需要大量資本投資和適當的基礎設施
    • 機會
      • 藥物的持續發展，以滿足醫學和神經病學領域獨特且不斷變化的需求
      • 中樞神經系統藥物研發中引入人工智慧和機器學習
    • 任務
      • 嚴格的產品核可法規和對產品召回的擔憂
      • 儘管有足夠的研究，但缺乏神經學領域的主題專業知識
  • 市場趨勢
  • COVID-19 的累積影響
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範
  • 客戶客製化

第6章 依藥物類別分類的中樞神經系統藥物市場

  • 止痛藥
  • 麻醉劑
  • 抗癲癇藥
  • 抗帕金森氏症藥物
  • 抗憂鬱症

第7章 依疾病區分的中樞神經系統藥物市場

  • 中樞神經系統創傷
  • 感染疾病
  • 精神健康
  • 神經退化性疾病
  • 神經血管疾病

第8章 中樞神經系統藥物市場（依藥物類型）

  • 生物製品
  • 非生物製品

第9章 中樞神經系統藥物市場：依分銷管道分類

  • 醫院藥房
  • 線上的
  • 零售藥房

第10章 美洲中樞神經系統藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太中樞神經系統藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲中樞神經系統藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭形勢

  • FPNV定位矩陣
  • 市佔率分析：主要企業
  • 競爭情境分析：主要企業
    • 併購
    • 合約、合作和夥伴關係

第14章上市公司名單

第15章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-434CCDA051A0

The Global Central Nervous System Drugs Market is forecasted to grow significantly, with a projected USD 20.71 billion in 2023 at a CAGR of 9.60% and expected to reach a staggering USD 39.99 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Central Nervous System Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Central Nervous System Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug Classes, market is studied across Analgesics, Anesthetics, Anti-Epileptics, Anti-Parkinson Drugs, and Antidepressant. The Analgesics commanded largest market share of 22.49% in 2022, followed by Antidepressant.

Based on Diseases, market is studied across CNS Trauma, Infectious Diseases, Mental Health, Neurodegenerative Diseases, and Neurovascular Diseases. The Infectious Diseases commanded largest market share of 28.56% in 2022, followed by Mental Health.

Based on Drug Type, market is studied across Biologics and Non-Biologics. The Non-Biologics commanded largest market share of 71.68% in 2022, followed by Biologics.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online, and Retail Pharmacies. The Retail Pharmacies commanded largest market share of 62.58% in 2022, followed by Hospital Pharmacies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 41.45% in 2022, followed by Americas.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Central Nervous System Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Central Nervous System Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Central Nervous System Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Central Nervous System Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Central Nervous System Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Central Nervous System Drugs Market?

6. What is the market share of the leading vendors in the Global Central Nervous System Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Central Nervous System Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Central Nervous System Drugs Market, by Drug Classes, 2022 vs 2030
  • 4.3. Central Nervous System Drugs Market, by Diseases, 2022 vs 2030
  • 4.4. Central Nervous System Drugs Market, by Drug Type, 2022 vs 2030
  • 4.5. Central Nervous System Drugs Market, by Distribution Channel, 2022 vs 2030
  • 4.6. Central Nervous System Drugs Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidence of neurological and cognitive disorders across the globe
      • 5.1.1.2. Ascending government programs and awareness activities to spread the knowledge about neurological risk factors and symptoms
      • 5.1.1.3. Rise in geriatric population with neurological complications
    • 5.1.2. Restraints
      • 5.1.2.1. Requirement of high capital investment and adequate infrastructure for drug discovery and development
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing drug evolvement to meet the unique and changing demands of psychiatry and neurology field
      • 5.1.3.2. Adoption of artificial intelligence and machine learning in CNS drug discovery
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations for product approvals and concern regarding product recalls
      • 5.1.4.2. Dearth of subject expertise in the neurological field amid the competent studies
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Central Nervous System Drugs Market, by Drug Classes

  • 6.1. Introduction
  • 6.2. Analgesics
  • 6.3. Anesthetics
  • 6.4. Anti-Epileptics
  • 6.5. Anti-Parkinson Drugs
  • 6.6. Antidepressant

7. Central Nervous System Drugs Market, by Diseases

  • 7.1. Introduction
  • 7.2. CNS Trauma
  • 7.3. Infectious Diseases
  • 7.4. Mental Health
  • 7.5. Neurodegenerative Diseases
  • 7.6. Neurovascular Diseases

8. Central Nervous System Drugs Market, by Drug Type

  • 8.1. Introduction
  • 8.2. Biologics
  • 8.3. Non-Biologics

9. Central Nervous System Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online
  • 9.4. Retail Pharmacies

10. Americas Central Nervous System Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Central Nervous System Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Central Nervous System Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player
    • 13.3.1. Merger & Acquisition
      • 13.3.1.1. Neuraxpharm announces closing of acquisition of established products from Sanofi
      • 13.3.1.2. Intrinsic Medicine enters merger deal with Phoenix Biotech
      • 13.3.1.3. Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement
      • 13.3.1.4. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
    • 13.3.2. Agreement, Collaboration, & Partnership
      • 13.3.2.1. Astex and Cardiff University announce drug discovery collaboration
      • 13.3.2.2. PrecisionLife and Ono sign multi-target partnership for CNS disorders
      • 13.3.2.3. Collaboration will focus on therapy targets for CNS disorders
      • 13.3.2.4. Gensaic enters into collaboration to develop
      • 13.3.2.5. IAMA Therapeutics Partners with the Italian Institute of Technology to Embark on Landmark Research on Neuroscience Drug Discovery
      • 13.3.2.6. AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases

14. List of Company Mentioned

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. CENTRAL NERVOUS SYSTEM DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2022 VS 2030 (%)
  • FIGURE 5. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2022 VS 2030 (%)
  • FIGURE 6. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2022 VS 2030 (%)
  • FIGURE 7. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • FIGURE 8. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 9. CENTRAL NERVOUS SYSTEM DRUGS MARKET DYNAMICS
  • FIGURE 10. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 18. CENTRAL NERVOUS SYSTEM DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 19. CENTRAL NERVOUS SYSTEM DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. CENTRAL NERVOUS SYSTEM DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 5. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANESTHETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTI-PARKINSON DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIDEPRESSANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 11. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS TRAUMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MENTAL HEALTH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NEUROVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. CENTRAL NERVOUS SYSTEM DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 192. CENTRAL NERVOUS SYSTEM DRUGS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 193. CENTRAL NERVOUS SYSTEM DRUGS MARKET LICENSE & PRICING